Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjunctive cholestyramine therapy for thyrotoxicosis

B L Solomon1, L Wartofsky, K D Burman

  • 1Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC 20307-5001.

Clinical Endocrinology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel biomarker <i>SYT12</i> may contribute to predicting papillary thyroid cancer outcomes.

Future science OA·2017
Same author

A 2013 European survey of clinical practice patterns in the management of Graves' disease.

Clinical endocrinology·2015
Same author

Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Hormones and behavior·2013
Same author

Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al.

Frontiers in neuroendocrinology·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Andrology·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Hormone research in paediatrics·2013

Cholestyramine, an adjunct to standard thyrotoxicosis therapy, significantly accelerated the decline of thyroid hormone levels in patients. This anion exchange resin demonstrated safety and efficacy, particularly in the initial weeks of treatment.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Thyrotoxicosis treatment typically involves beta-blockers and thionamides.
  • Increased enterohepatic circulation of thyroid hormones (T4 and T3) is observed in thyrotoxicosis.

Purpose of the Study:

  • To investigate if cholestyramine, an anion exchange resin, can enhance the efficacy of standard thyrotoxicosis therapy.
  • To determine if adjunctive cholestyramine accelerates the reduction of serum iodothyronine levels.

Main Methods:

  • A double-blind, placebo-controlled, cross-over study involving 15 thyrotoxicosis patients.
  • Patients received standard therapy (atenolol, methimazole) with either cholestyramine or placebo for two weeks, followed by a washout and cross-over.
  • Serum levels of total and free thyroxine (T4) and triiodothyronine (T3) were measured weekly.

Related Experiment Videos

Main Results:

  • The cholestyramine group exhibited a more rapid decline in all thyroid hormone levels compared to the placebo group in Phase 1.
  • An additional decline in free thyroxine was observed in Phase 2 for cholestyramine patients, though the overall rate of decline did not differ.
  • Immunoglobulin levels remained unaffected by cholestyramine treatment.

Conclusions:

  • Cholestyramine is a safe and effective adjunctive treatment for thyrotoxicosis.
  • The primary benefit of cholestyramine appears to be during the initial weeks of therapy.